These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 24819935

  • 1. Stimulant and other substance use disorders in schizophrenia: prevalence, correlates and impacts in a population sample.
    Sara GE, Burgess PM, Malhi GS, Whiteford HA, Hall WC.
    Aust N Z J Psychiatry; 2014 Nov; 48(11):1036-47. PubMed ID: 24819935
    [Abstract] [Full Text] [Related]

  • 2. Differences in associations between cannabis and stimulant disorders in first admission psychosis.
    Sara G, Burgess P, Malhi GS, Whiteford H, Hall W.
    Schizophr Res; 2013 Jul; 147(2-3):216-22. PubMed ID: 23684162
    [Abstract] [Full Text] [Related]

  • 3. [Cannabis and schizophrenia: demographic and clinical correlates].
    Dervaux A, Laqueille X, Bourdel MC, Leborgne MH, Olié JP, Lôo H, Krebs MO.
    Encephale; 2003 Jul; 29(1):11-7. PubMed ID: 12640322
    [Abstract] [Full Text] [Related]

  • 4. Cannabis and stimulant disorders and readmission 2 years after first-episode psychosis.
    Sara GE, Burgess PM, Malhi GS, Whiteford HA, Hall WC.
    Br J Psychiatry; 2014 Jun; 204(6):448-53. PubMed ID: 24578446
    [Abstract] [Full Text] [Related]

  • 5. Stimulant use disorders: characteristics and comorbidity in an Australian population sample.
    Sara G, Burgess P, Harris M, Malhi GS, Whiteford H, Hall W.
    Aust N Z J Psychiatry; 2012 Dec; 46(12):1173-81. PubMed ID: 22990432
    [Abstract] [Full Text] [Related]

  • 6. The impact of cannabis and stimulant disorders on diagnostic stability in psychosis.
    Sara GE, Burgess PM, Malhi GS, Whiteford HA, Hall WC.
    J Clin Psychiatry; 2014 Apr; 75(4):349-56. PubMed ID: 24813404
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Reasons for increased substance use in psychosis.
    Gregg L, Barrowclough C, Haddock G.
    Clin Psychol Rev; 2007 May; 27(4):494-510. PubMed ID: 17240501
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cannabis and Alcohol Abuse Among First Psychotic Episode Inpatients.
    Katz G, Kunyvsky Y, Hornik-Lurie T, Raskin S, Abramowitz MZ.
    Isr J Psychiatry Relat Sci; 2016 May; 53(3):10-15. PubMed ID: 28492376
    [Abstract] [Full Text] [Related]

  • 18. [Sociodemographic profiles, addictive and mental comorbidity in cannabis users in an outpatient specific setting].
    Guillem E, Pelissolo A, Vorspan F, Bouchez-Arbabzadeh S, Lépine JP.
    Encephale; 2009 Jun; 35(3):226-33. PubMed ID: 19540408
    [Abstract] [Full Text] [Related]

  • 19. Specific impact of stimulant, alcohol and cannabis use disorders on first-episode psychosis: 2-year functional and symptomatic outcomes.
    Ouellet-Plamondon C, Abdel-Baki A, Salvat É, Potvin S.
    Psychol Med; 2017 Oct; 47(14):2461-2471. PubMed ID: 28424105
    [Abstract] [Full Text] [Related]

  • 20. Psychopathologic differences between cannabis-induced psychoses and recent-onset primary psychoses with abuse of cannabis.
    Rubio G, Marín-Lozano J, Ferre F, Martínez-Gras I, Rodriguez-Jimenez R, Sanz J, Jimenez-Arriero MA, Carrasco JL, Lora D, Jurado R, López-Trabada JR, Palomo T.
    Compr Psychiatry; 2012 Nov; 53(8):1063-70. PubMed ID: 22682680
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.